GRP-109 Lenalidomide: Haematological Safety Profile
نویسندگان
چکیده
منابع مشابه
Cytogenetic Profile of 109 Lipomas1
Cytogenetic analysis of short-term cultures was carried out on 109 lipomas from 92 patients. Clonal chromosomal abnormalities were pres ent in 50% of the tumors analyzed. Based on the results, three main Cytogenetic groups were identified and included: (a) tumors with normal karyotypes, (b) tumors with abnormalities involving region ql3-15 on chromosome 12, and (c) tumors with other clonal aber...
متن کاملCytogenetic profile of 109 lipomas.
Cytogenetic analysis of short-term cultures was carried out on 109 lipomas from 92 patients. Clonal chromosomal abnormalities were present in 50% of the tumors analyzed. Based on the results, three main cytogenetic groups were identified and included: (a) tumors with normal karyotypes, (b) tumors with abnormalities involving region q13-15 on chromosome 12, and (c) tumors with other clonal aberr...
متن کاملHaematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.
To the Editor: Refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) is a rare entity and is defined as an overlap syndrome with clinical and morphologic features of both myelodysplastic syndrome (MDS) and BCR-ABL-negative myeloproliferative neoplasm, including marked thrombocytosis associated with abnormal megakaryocytes (1). Mutations in the Janus Kinase 2 gene (JAK2) and/or S...
متن کاملEfficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
INTRODUCTION Cutaneous lupus erythematosus (CLE) is a chronic disease characterized by disfigurement and a relapsing course. Thalidomide has proven its efficacy in refractory cutaneous lupus disease, although it is not exempt from significant side effects and frequent relapses after withdrawal. New thalidomide analogues have been developed but lack clinical experience. The aim of this prelimina...
متن کاملApproaches to Managing Safety With Lenalidomide in Hematologic Malignancies
Lenalidomide is an oral immunomodulatory agent approved in relapsed multiple myeloma with dexamethasone, for transfusion-dependent anemia in myelodysplastic syndrome associated with deletion 5q, and in relapsed/progressive mantle cell lymphoma following bortezomib. In recent clinical trials, lenalidomide has shown promising activity in hematologic malignancies, including chronic lymphocytic leu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.109